Clinical Trial Update: Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of lenalidomide with autologous mature dendritic cells pulsed with KRN7000 in multiple myeloma; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Autologous mature dendritic cells pulsed with KRN7000 (dendritic cells pulsed with KRN7000)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Yale University | Conditions: Myeloma | Phase 1 | Status: COMPLETED